

CardiologyRounds®

www.cardiologyrounds.org

AS PRESENTED IN THE ROUNDS OF THE CARDIOVASCULAR DIVISION
OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS

The Road to Wasting is Paved with Lost Minerals

By KARL T. WEBER, MD

Congestive heart failure (CHF), with its characteristic signs and symptoms, is a major health problem of epidemic proportions, particularly amongst the elderly. It is now recognized that this clinical syndrome involves more than a failing heart and salt-avid kidneys. In reaching beyond the traditional cardiorenal perspective, there is the realization that the neurohormonal activation found in CHF is accompanied by a systemic illness that contributes to its progressive nature and downhill clinical course. This issue of *Cardiology Rounds* reviews an emerging body of experimental and clinical evidence that addresses the pathogenic mechanisms involved in the appearance of this illness and its pathophysiologic expressions. These include oxidative stress in diverse tissues, immune cell activation, and a loss of soft tissues and bone that eventuates in a wasting syndrome termed “cardiac cachexia.” In brief, the evidence suggests that “the road to wasting is paved with lost minerals.”

Lost macronutrients – calcium (Ca^{2+}) and magnesium (Mg^{2+}) – contribute to the appearance of secondary hyperparathyroidism (SHPT), with parathyroid hormone (PTH)-mediated intracellular Ca^{2+} overloading that induces oxidative stress in diverse cells. In peripheral blood mononuclear cells (PBMCs; lymphocytes and monocytes), these events account for an immunostimulatory state. Lost micronutrients, zinc (Zn) and selenium (Se), reduce the activities of respective metallo-enzyme-dependent endogenous antioxidant defenses. These trace mineral deficiencies have been associated with cardiomyopathy. In translational studies conducted in African-Americans (AAs) living in Memphis, SHPT, together with hypovitaminosis D, hypozincemia, and hyposelenemia, were found to be co-variants of CHF.

CHF – A salt-avid state

CHF is a clinical syndrome consisting of signs and symptoms that arise from congested organs and hypo-perfused tissues. Its origins are rooted in a salt-avid state, where the urinary sodium/potassium (Na/K) ratio is <1.0 . CHF is largely mediated by effector hormones of the circulating renin-angiotensin-aldosterone system (RAAS) (Figure 1). RAAS activation is based on impaired renal perfusion, in which angiotensin II and aldosterone (ALDO) overwhelm the biologic actions of atrial and brain natriuretic peptides that maintain urinary Na excretion (urinary Na/K >1.0), euvoemia, and clinical compensation. Elevations in plasma renin activity, angiotensin II, and ALDO are integral features of the “volume-overloaded” state, expressed as expanded intra- and extravascular volumes, and clinical decompensation found with CHF.^{1,2}

It is important to recognize that, in patients experiencing chronic cardiac failure with systolic dysfunction, reduced ejection fraction (EF) does not predict cardiac output or the amount of systemic blood flow apportioned to the kidneys. Accordingly, EF neither predicts RAAS activation, salt and water retention, nor the clinical severity of heart failure.



BRIGHAM AND
WOMEN'S HOSPITAL



HARVARD
MEDICAL SCHOOL
TEACHING AFFILIATE

Cardiovascular Division (Clinical)

| | |
|--------------------------|--------------------------|
| Dale Adler, MD | Jane A. Leopold, MD |
| Christine Albert, MD | Eldrin Lewis, MD |
| Michelle Albert, MD | James Liao, MD |
| Elliott Antman, MD | Peter Libby, MD |
| Donald S. Baim, MD | (Division Chief) |
| Kenneth Baughman, MD | Leonard Lilly, MD |
| Joshua Beckman, MD | Bernard Lown, MD |
| Charles M. Blatt, MD | Laura Mauri, MD |
| Eugene Braunwald, MD | Thomas Michel, MD, PhD |
| Christopher Cannon, MD | David Morrow, MD |
| Ming Hui Chen, MD | Karen Moulton, MD |
| Michael Chin, MD, PhD | Gilbert Mudge, MD |
| Mark Creager, MD | Anju Nohria, MD |
| Akshay Desai, MD | Patrick O'Gara, MD |
| Elazer Edelman, MD, PhD | Marc A. Pfeffer, MD, PhD |
| Andrew Eisenhauer, MD | (Editor) |
| Laurence Epstein, MD | Jorge Plutzky, MD |
| James Fang, MD | Jeffrey Popma, MD |
| David Faxon, MD | Shmuel Ravid, MD |
| Mark Feinberg, MD | Frederic Resnic, MD |
| Daniel Forman, MD | Paul Ridker, MD |
| Peter Ganz, MD | Thomas Rocco, MD |
| J. Michael Gaziano, MD | Campbell Rogers, MD |
| Thomas Gaziano, MD | Maria Rupnick, MD, PhD |
| Marie Gerhard-Herman, MD | Marc Sabatine, MD |
| Robert Giugliano, MD | Arthur Sasahara, MD |
| Michael Givertz, MD | Christine Seidman, MD |
| Samuel Z. Goldhaber, MD | Andrew Selwyn, MD |
| Thomas B. Graboys, MD | Daniel Simon, MD |
| Howard Hartley, MD | Laurence Sloss, MD |
| Carolyn Ho, MD | Piotr Sobieszczyk, MD |
| Mukesh Jain, MD | Regina Sohn, MD |
| John Jarcho, MD | Scott Solomon, MD |
| Paula Johnson, MD | Lynne Stevenson, MD |
| Scott Kinlay, MD | William Stevenson, MD |
| Jamil Kirdar, MD | Peter Stone, MD |
| James Kirshenbaum, MD | Michael Sweeney, MD |
| Bruce Koplan, MD | Usha Tedrow, MD |
| Raymond Kwong, MD | Stephen Wiviott, MD |
| Michael J. Landzberg, MD | Justina Wu, MD |
| Richard Lee, MD | |


Brigham and Women's Hospital

Fax: (617) 732-5291 Website: www.heartdoc.org

The editorial content of *Cardiology Rounds* is determined solely by the Cardiovascular Division of Brigham and Women's Hospital. This publication is made possible by an educational grant.

Cardiology Rounds is approved by the Harvard Medical School Department of Continuing Education to offer continuing education credit

Figure 1: Compensated and decompensated heart failure (HF) is based on the respective absence or presence of urinary Na⁺ retention, accompanied by signs and symptoms of expanded intra- and extravascular volumes. In compensated HF, with mild to moderate reductions in renal perfusion, natriuretic peptides, eg. atrial natriuretic peptide (ANP), released by distended atria stimulate Na⁺ excretion so that the urinary Na⁺/K⁺ ratio is >1.0. Moderate to severe reductions in renal perfusion activate the renin-angiotensin-aldosterone system (RAAS), overriding the action of natriuretic peptides to stimulate nearly complete urinary Na⁺ resorption with the urinary Na⁺/K⁺ ratio <1.0.



Reproduced from Weber KT. *N Engl J Med* 2001;345:1689-1697 with permission.

CHF – A systemic illness

The broader perspective of CHF recognizes its systemic nature with these prominent features:

- the presence of oxidative stress with reactive oxygen and nitrogen species that overwhelm endogenous antioxidant defenses in such diverse tissues as skin, skeletal muscle, PBMCs, and blood
- an immuno-stimulatory state with activated PBMCs and elevations in circulating chemokines and cytokines
- a catabolic state with loss of soft tissues and bone that begets cachexia.³

An experimental model

The complex neurohormonal profile found in CHF includes elevated circulating levels of angiotensin II, ALDO, catecholamines, endothelin-1, atrial and brain natriuretic peptides, and arginine vasopressin. Our experimental studies have focused on chronic aldosteronism, where plasma renin activity and angiotensin II are suppressed. In uninephrectomized rats, aldosterone/salt treatment (ALDOST) consists of an implanted minipump that releases ALDO subcutaneously (0.75 µg/h) to raise plasma levels to those found in human CHF and which are inappropriate for dietary Na⁺ intake that consists of 1% sodium chloride (NaCl) in drinking water. A 0.4% potassium chloride (KCl) supplement is provided to prevent hypokalemia.

Using this model, we (and others) have identified the presence of oxidative stress in blood, PBMCs, and immune


cells that invade the cardiovascular system.^{4,8} This includes multiple lines of evidence: activation of gp91^{phox}, a nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase subunit; the presence of 3 nitrotyrosine, a stable endproduct of short-lived peroxynitrite formation derived from the reaction between superoxide and nitric oxide; activation of a redox-sensitive nuclear transcription factor (NF)κB, and upregulated expression of the proinflammatory genes it controls, including intercellular adhesion molecule (ICAM)1, monocyte chemoattractant protein (MCP)1, and tumor necrosis factor (TNF)α. Co-treatment with various antioxidants has proven vasculoprotective.^{4,7-11}

Mechanisms responsible for the induction of oxidative stress in PBMCs were targeted for investigation. In keeping with the findings of Delva et al¹² in human lymphocytes harvested from patients with aldosteronism, we hypothesized that a fall in intracellular cytosolic-free [Mg²⁺]_i and a putative reduction in Na⁺/K⁺ adenosine triphosphatase (ATPase) activity would lead to increased Ca²⁺ entry with the rise in intracellular Ca²⁺ contributing to the induction of oxidative stress. An early and persistent fall in PBMC cytosolic-free [Mg²⁺]_i was found in ALDOST that was accompanied by a rise in total and cytosolic-free [Ca²⁺]_i and an associated increased production of H₂O₂ by lymphocytes and monocytes, together with upregulated mRNA expression of antioxidant defenses and adhesion molecules.^{5,6} These cellular responses were attenuated when rats with ALDOST were co-treated with spironolactone (spiro), an ALDO receptor antagonist.⁶ Collectively, these findings suggest a direct response of circulating lymphocytes and monocytes to ALDOST and, when *in vitro* studies suggested the involvement of a Na⁺-dependent, the ALDO receptor-mediated Na⁺/Mg²⁺ exchanger.¹² PBMCs have cytosolic mineralocorticoid receptors.¹³

Other known aspects of aldosteronism, however, suggested an alternate explanation. Conn noted that hypomagnesemia was a cardinal feature of aldosteronism,¹⁴ while Horton and Biglieri¹⁵ demonstrated that the hypermagnesuria that accompanies it can be attenuated by spiro or adrenal surgery. We, therefore, elected to pursue another line of investigation (Figure 2) that focused on Mg²⁺ and Ca²⁺ excretion by kidneys and colon, given that these tissues are sites of high-density ALDO receptor binding.¹⁶

Metabolic studies, in which 24-hour urinary and fecal Ca²⁺ and Mg²⁺ excretion were monitored, were conducted in rats receiving ALDOST for 1-6 weeks.^{17,18} Compared to age and gender-matched controls on an identical diet, a marked increase in the urinary and fecal excretion of these divalent cations was observed throughout the 1-6 weeks on ALDOST, which was attenuated at each site by spiro co-treatment. In urine, microgram levels of Ca²⁺ and Mg²⁺ were lost while, in feces, milligram quantities were found. In association with these losses, an early and persistent fall in plasma-ionized [Ca²⁺]_o and [Mg²⁺]_o was demonstrated that was accompanied by an elevation in plasma PTH.

Figure 2: A paradigm depicting the appearance of secondary hyperparathyroidism with elevations in circulating parathyroid hormone (PTH). Elevations in circulating PTH may accompany aldosteronism, long-term furosemide treatment, and hypovitaminosis D with reduced stores of 25(OH)D. In addition to promoting bone resorption, PTH causes intracellular Ca^{2+} overloading with induction of oxidative stress and, when H_2O_2 contributes to signal transduction, it eventuates in immune cell activation and a proinflammatory phenotype. Urinary Zn and Se excretion are increased during aldosteronism and in response to ACE inhibitor (ACEI) or AT1 receptor antagonist (ARB) treatment with resultant hypozincemia and hyposelenemia contributing to reduced activities of Cu/Zn superoxide dismutase (SOD) and Se-glutathione peroxidase (GSH-Px).



Reproduced from Bhattacharya SK et al. *Heart Fail Rev* 2006 (In press) with permission.

In keeping with the presence of SHPT, the resorption of bone manifested as a reduction in bone mineral density of the tibia and femur and a fall in their strength to flexor stress. In concert with the elevations in PTH was an excessive accumulation of intracellular Ca^{2+} in PBMC, heart, and skeletal muscle. The SHPT found in chronic renal failure is known to be accompanied by intracellular Ca^{2+} overloading of diverse cells and can be prevented by administration of a Ca^{2+} channel blocker.¹⁹

Our hypothesis was therefore revised (Figure 2) to suggest that PTH-mediated intracellular Ca^{2+} overloading plays a permissive role in the appearance of oxidative stress in PBMC. Accordingly, parathyroidectomy (PTx) was performed prior to ALDOST.²⁰ PTx abrogated Ca^{2+} overloading in PBMCs, as well as in heart and skeletal muscle, and prevented the appearance of oxidative stress. This was evident by downregulated PBMC H_2O_2 production and a fall in plasma α_1 -antiproteinase activity, an inverse correlate of oxidative stress. In preventing urinary and fecal losses of these cations, spiro co-treatment also mitigated SHPT.¹⁸ The importance of intracellular Ca^{2+} loading as a prerequisite to the induction of oxidative

stress in PBMC was further demonstrated by the protective response to amlodipine co-treatment.²¹

Clinical correlates

These experimental studies draw attention to the importance of Ca^{2+} and Mg^{2+} balance in patients with heart failure. Elevations in serum PTH have been reported in patients with advanced CHF awaiting cardiac transplantation (in whom elevations in serum ALDO are expected), who have been treated long-term with a loop diuretic (which augments urinary Ca^{2+} and Mg^{2+} excretion above that seen with aldosteronism alone).²²⁻²⁴ Moreover, many of these patients were found to have reductions in bone mineral density to levels in keeping with osteopenia and osteoporosis. Among nursing home residents, daily furosemide dosage is an important predictor of SHPT.²⁵

Circulating levels of interleukin (IL)-6 and $\text{TNF}\alpha$ increase in patients with CHF, irrespective of their etiologic origins.^{26,27} These cytokines are also elevated in patients with primary or SHPT and are derived from osteoblasts that are influenced by PTH to promote osteoclastogenesis and bone resorption.²⁸ It is presently unclear if the elevated serum IL-6 and $\text{TNF}\alpha$ levels found in CHF patients are markers of SHPT.

Translational studies in African-Americans with CHF. macro- and micronutrients

Macronutrients are chemical elements (eg, carbon, hydrogen, nitrogen, oxygen, phosphorus, and sulfur) that are essential to life in large quantities. Other macronutrients include calcium, magnesium, sodium, and potassium.

During 2005, translational studies were conducted in AAs followed at the Regional Medical Center in Memphis, Tennessee. In February, 9 patients (aged 33-60 years; 8 AAs) were hospitalized because of decompensated heart failure, expressed as signs and symptoms of salt and water retention due to systolic dysfunction (ejection fraction <35%) and an ischemic or dilated cardiomyopathy. Five were newly diagnosed and untreated prior to admission and 4 were treated with an ACE inhibitor, furosemide, a loop diuretic, and spiro.²⁹ Serum PTH (mean \pm SEM) was elevated above the normal range (6-65 pg/mL) in all 9; the levels were 204 ± 60 and 134 ± 14 pg/mL in untreated and treated patients, respectively. Calculated creatinine clearance did not differ significantly between untreated and treated patients (74 ± 15 and 83 ± 21 mL/min, respectively). Plasma-ionized $[\text{Ca}^{2+}]_o$ was not measured. Thus, SHPT was present in AAs with untreated CHF, in whom the impact of furosemide on urinary Ca^{2+} and Mg^{2+} excretion could be discounted, as well as in those with treated CHF. Therefore, one must take aldosteronism into consideration, given the expected activation of the RAAS that contributes to active salt and water retention in decompensated failure.

From June to December, 40 additional AA patients (aged 31–79 years) were studied.³⁰ These included 15 hospitalized patients with signs and symptoms of protracted CHF (≥ 4 weeks); 15 hospitalized patients with signs and symptoms of shorter duration CHF (1–2 weeks); and 10 outpatients with compensated failure. All had systolic dysfunction (EF $< 35\%$) of ischemic or idiopathic (dilated) cardiomyopathy origin. The majority were treated with either an ACE inhibitor or an AT₁ receptor antagonist (ARB), furosemide, and spiro. Serum PTH was abnormally elevated in all 15 patients with protracted CHF and in 60% of patients with short-term CHF, but in none of the 10 compensated patients. In patients with decompensated CHF of ≥ 4 weeks duration and in those with CHF of shorter duration (1–2 weeks), serum-ionized [Ca²⁺]_i fell below the expected normal range (1.12–1.30 mmol/L). Serum-ionized [Mg²⁺]_i in decompensated CHF of ≥ 4 weeks duration and 1–2 weeks duration also fell below the normal range (0.53–0.67 mmol/L). None of these patients had sepsis, pancreatitis, blood transfusion, surgery, chronic alcoholism, or metabolic alkalosis that would lead to reduced ionized [Ca²⁺]_i or [Mg²⁺]_i.

Evidence of hypovitaminosis D with reduced serum 25(OH)D (< 30 ng/mL) was found in all 15 patients with CHF of ≥ 4 weeks duration, in 80% of those with CHF of 1–2 weeks duration, and in 80% with compensated failure. Calculated creatinine clearance was statistically indistinguishable amongst the 3 groups. In 9 AA normal volunteers (3 men, 6 women; median age 36 years, 24–58 years), of comparable gender and age to the AA patients with heart failure (but without historical or clinical evidence of cardiovascular disease), serum PTH and 25(OH)D were normal. **Micronutrients** are essential to life, but only in small quantities (< 100 mg/day). Vitamins and trace minerals (eg, zinc, selenium, iron, and copper) are micronutrients obtained predominantly from dietary intake that are not synthesized by the body.

There is a prevalence of dilated cardiomyopathy in general populations where micronutrient dietary deficiencies are found, such as in the Se-poor soil in Keshan province in China, or in patients administered parenteral nutrition that is deficient in Zn and/or Se.^{31–33} A redistribution of Zn and Se from the vascular compartment into tissues may occur in chronic illness and it has been suggested that this is a predisposing factor to the genesis of a dilated (idiopathic) cardiomyopathy.^{34,35} Incidentally, hypozincemia has been reported in patients with a dilated cardiomyopathy.^{36,37} Of interest, urinary Zn excretion is increased in response to ACE inhibitor or ARB treatment, but not with loop diuretics. Urinary Zn excretion has been held responsible for the appearance of hypozincemia and an associated impairment in taste (dysgeusia)

reported in patients with CHF treated with these agents.^{38–41} A redistribution of trace minerals from tissues has also been reported in response to captopril.⁴²

In addition to reduced serum-ionized [Ca²⁺]_i and [Mg²⁺]_i, elevated PTH, and hypovitaminosis D in AAs with CHF, we found that serum Zn fell below the normal range (75–140 $\mu\text{g/dL}$) in many of the 40 patients noted above (in $> 70\%$ of patients with protracted CHF; in $> 50\%$ with short-term CHF; and in 5 of 10 with compensated failure). Serum Se was also reduced below the normal range (85–125 $\mu\text{g/L}$) in $> 90\%$ of these patients (in all 15 with protracted CHF; in 60% with short-term CHF; and in 9 of 10 with compensated failure).

Zn and Se are integral to the activity of oxidoreductases that serve as antioxidant defenses. Together, Cu/Zn superoxide dismutase (SOD) and Se glutathione peroxidase (GSH-Px) protect against superoxide- and H₂O₂-induced cytotoxicity. We are currently monitoring the activity of these oxidoreductases to determine the functional significance of the hypozincemia and hyposelenemia found in our AA patients.

Thus, in many AA patients with CHF, SHPT is a common covariant of CHF, together with hypovitaminosis D, hypozincemia, and hyposelenemia. However, in our AA patients with either decompensated or compensated failure, the pathophysiologic mechanisms responsible remain to be elucidated. Several possibilities may be considered.

- One possibility is the presence of aldosteronism in patients with decompensated failure having signs and symptoms of salt and water retention and in whom, acidification of urine and feces is accompanied by increased excretion of Ca²⁺ and Zn.^{43–45}
- Secondly, SHPT is associated with hyperzincuria.⁴⁶
- Third, a majority of our patients, both compensated and decompensated, are being treated with either an ACE inhibitor or an AT₁ receptor antagonist, both of which are known to increase urinary Zn excretion and may be accompanied by hypozincemia.

Amongst the ACE inhibitors, it has been suggested that those containing a sulfhydryl group (eg, captopril, zofenopril) are much more likely to bind Zn, leading to hyperzincuria. However, this is not a consistent finding.^{47,48} Reduced Zn levels in PBMCs have been reported with either captopril or enalapril.⁴⁷

Summary and conclusions

An emerging body of evidence suggests that SHPT is an important co-variant of CHF, especially in AAs, in whom hypovitaminosis D with reduced serum 25(OH)D levels are prevalent. This is because melanin mandates prolonged exposure of the skin to sunlight and its UVB component, both of which are necessary for vitamin D synthesis. Moreover, melanin absorbs heat, which can lead patients to

avoid sunlight. Finally, a housebound lifestyle imposed by symptomatic CHF limits outdoor activities and, hence, exposure to sunlight. In addition to the role of hypovitaminosis D in contributing to SHPT, there are increased urinary and fecal losses of macronutrients Ca^{2+} and Mg^{2+} associated with aldosteronism, as well as heightened urinary losses of these macronutrients with furosemide treatment. Thus, the precarious Ca^{2+} balance seen with reduced serum 25(OH)D is further compromised when AAs develop CHF with circulating RAAS activation and are then treated with a loop diuretic. SHPT accounts for a paradoxical Ca^{2+} overloading and induction of oxidative stress in diverse tissues that spills over to the systemic circulation.

In addition to SHPT, hypozincemia and hyposelenemia may be present in AAs with treated compensated and decompensated heart failure. Deficiencies in these micronutrients may originate from dietary insufficiencies, altered rates of absorption or excretion, and/or tissue redistribution. Well over 80% of the 40 AA patients that we have studied to date have an idiopathic (dilated) cardiomyopathy.³⁰ Zn and Se deficiencies may contribute to the severity of heart failure and its progressive nature in this population. Collectively, these findings support the need for nutraceutical treatment, in addition to current pharmaceuticals, in AAs with heart failure, and focus attention on minerals that are lost along the road to wasting and their associated adverse consequences.

Reference List

- Swedberg K, Eneroth P, Kjekshus J, Wilhelmssen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. *Circulation* 1990;82:1730-1736.
- Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation* 1990;82:1724-1729.
- Weber KT. The proinflammatory heart failure phenotype: a case of integrative physiology. *Am J Med Sci* 2005;330:219-226.
- Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. *Am J Pathol* 2002;161:1773-1781.
- Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. *Am J Physiol Heart Circ Physiol* 2003;285:H813-H821.
- Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. *Circ Res* 2003;93:e124-e135.
- Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. *Hypertension* 2002;40:504-510.
- Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. *Hypertension* 2003;42:49-55.
- Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. *Am J Hypertens* 2004;17:597-603.
- Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelinA-NADPH oxidase pathway in low-renin hypertension. *Circulation* 2003;107:1053-1058.
- Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. *Biochem Biophys Res Commun* 2004;313:812-817.
- Delva P, Pastori C, Degan M, Montesi G, Brazzarola P, Lechi A. Intralymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. *Hypertension* 2000;35:113-117.
- Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. *Am J Physiol* 1985;248:E388-E390.
- Conn JW. Aldosteronism in man. Some clinical and climatological aspects. Part II. *JAMA* 1963;183:871-878.
- Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. *J Clin Endocrinol Metab* 1962;22:1187-1192.
- Sheppard K, Funder JW. Mineralocorticoid specificity of renal type I receptors: in vivo binding studies. *Am J Physiol* 1987;252 (2 Pt 1):E224-E229.
- Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. *Am J Physiol Heart Circ Physiol* 2004;287:H2023-H2026.
- Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. *Circulation* 2005;111:871-878.
- Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. *Semin Nephrol* 1994;14:219-231.
- Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. The calcium paradox of aldosteronism and the role of the parathyroid glands. *Am J Physiol Heart Circ Physiol* 2006;290:H286-H294.
- Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT. Aldosteronism and a proinflammatory vascular phenotype. Role of Mg^{2+} , Ca^{2+} and H_2O_2 in peripheral blood mononuclear cells. *Circulation* 2005;111:51-57.
- Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. *Am J Med* 1994;96:35-41.
- Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. *Am J Med* 1997;103:197-207.
- Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. *J Am Coll Cardiol* 2005;46:142-146.
- Stein MS, Scherer SC, Walton SL, et al. Risk factors for secondary hyperparathyroidism in a nursing home population. *Clin Endocrinol (Oxf)* 1996;44:375-383.
- Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. *Circulation* 1997;96:526-534.
- Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. *J Am Coll Cardiol* 1998;31:391-398.
- Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. *J Clin Endocrinol Metab* 1996;81:3450-3454.
- Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. *Am J Med Sci* 2006;331:30-34.
- Arroyo M, LaGuardia SP, Bhattacharya SK, et al. Hypozincemia and hyposelenemia in African-Americans with decompensated and compensated heart failure [abstr]. *J Investig Med* 2006;54 (Suppl 1; manuscript submitted):S302.
- Xia YM, Hill KE, Burk RF. Biochemical studies of a selenium-deficient population in China: measurement of selenium, glutathione peroxidase and other oxidant defense indices in blood. *J Nutr* 1989;119:1318-1326.
- van Rij AM, Thomson CD, McKenzie JM, Robinson MF. Selenium deficiency in total parenteral nutrition. *Am J Clin Nutr* 1979;32:2076-2085.
- Reeves WC, Marcuard SP, Willis SE, Movahed A. Reversible cardiomyopathy due to selenium deficiency. *JPEN* 1989;13:663-665.
- Sullivan JF, Blotcky AJ, Jetton MM, Hahn HK, Burch RE. Serum levels of selenium, calcium, copper magnesium, manganese and zinc in various human diseases. *J Nutr* 1979;109:1432-1437.
- Kavanaugh-McHugh AL, Ruff A, et al. Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome. *JPEN* 1991;15:347-349.

36. Ripa S, Ripa R, Giustiniani S. Are failed cardiomyopathies a zinc-deficit related disease? A study on Zn and Cu in patients with chronic failed dilated and hypertrophic cardiomyopathies. *Minerva Med* 1998;89:397-403.
37. Oster O. Trace element concentrations (Cu, Zn, Fe) in sera from patients with dilated cardiomyopathy. *Clin Chim Acta* 1993;214:209-218.
38. Zumkley H, Bertram HP, Vetter H, Zidek W, Losse H. Zinc metabolism during captopril treatment. *Horm Metab Res* 1985;17:256-258.
39. Koren-Michowitz M, Dishy V, Zaidenstein R, et al. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. *Am J Hypertens* 2005;18:358-363.
40. Wester PO. Urinary zinc excretion during treatment with different diuretics. *Acta Med Scand* 1980;208:209-212.
41. Abu-Hamdan DK, Desai H, Sondheimer J, Felicetta J, Mahajan S, McDonald F. Taste acuity and zinc metabolism in captopril-treated hypertensive male patients. *Am J Hypertens* 1988;1 (3 Pt 3):303S-308S.
42. Kotsaki-Kovatsi VP, Koehler-Samouilidis G, Kovatsis A, Rozos G. Fluctuation of zinc, copper, magnesium and calcium concentrations in guinea pig tissues after administration of captopril (SQ 14225). *J Trace Elem Med Biol* 1997;11:32-36.
43. Seal CJ, Heaton FW. Effect of dietary picolinic acid on the metabolism of exogenous and endogenous zinc in the rat. *J Nutr* 1985;115:986-993.
44. Lemann J, Jr., Gray RW, Maierhofer WJ, Cheung HS. The importance of renal net acid excretion as a determinant of fasting urinary calcium excretion. *Kidney Int* 1986;29:743-746.
45. Welbourne TC, Francoeur D. Influence of aldosterone on renal ammonia production. *Am J Physiol* 1977;233:E56-E60.
46. Malette LE, Henkin RI. Altered copper and zinc metabolism in primary hyperparathyroidism. *Am J Med Sci* 1976;272:167-174.
47. Golik A, Zaidenstein R, Dishy V, et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. *J Am Coll Nutr* 1998;17:75-78.
48. Rubio-Luengo MA, Maldonado-Martin A, Gil-Extremera B, Gonzalez-Gomez L, Luna del Castillo JD. Variations in magnesium and zinc in hypertensive patients receiving different treatments. *Am J Hypertens* 1995; 8:689-695.



Dr. Karl T. Weber is the Neuton Stern Professor of Cardiovascular Medicine and Director of the Division of Cardiovascular Diseases at the University of Tennessee Health Science Center. He received his medical degree from Temple University School of Medicine and served his residency in internal

medicine and fellowship in cardiology at the University of Alabama at Birmingham. Dr. Weber joined the Department of Medicine, Cardiovascular-Pulmonary Division, at the University of Pennsylvania as Assistant Professor in 1974, later becoming Associate Professor of Medicine and Director of the Cardio-Pulmonary Research Laboratories. In 1983, Dr. Weber was appointed Director of the Cardiology Division and Cardiovascular Institute of the Michael Reese Hospital and Medical Center and Harold H. Hines, Jr. Professor of Medicine at the University of Chicago. He joined the University of Missouri Health Sciences Center in 1990, serving as Chairman of the Department of Internal Medicine and Director of the Division of Cardiology through 1997. Dr. Weber's research interests (NIH-funded since 1974) have focused on heart failure, its pathogenic origins and pathophysiologic expressions. He is a pioneer in elucidating the importance of the heart's extracellular matrix and mechanisms responsible for cardiac fibrosis. Dr. Weber has authored over 500 publications and serves on US and international editorial boards. He was elected President of the Central Society for Clinical Research (1995-96) and the International Society for Heart Research, North American Section (1997-2000). Dr. Weber is the recipient of Moravian College (1987) and Temple University School of Medicine (1998) Alumni Achievement Awards and, in 2002, was elected into the International Academy of Cardiovascular Sciences (IACS). In 2005, he became President of the IACS/American Section and received the Makato Nagano Award for Distinguished Achievements in Cardiovascular Research. His current basic and translational research interests focus on congestive heart failure as a systemic illness and, in particular, its expression in African-Americans.

Disclosure: Dr. Weber has no disclosures to declare in association with the enclosed CME program.

**Harvard Medical School
Department of Continuing Medical Education
Brigham and Women's Hospital,
Department of Medicine**

**Thrombosis and Thromboembolism –
Course #: 00261495**

October 12-13, 2006

The Fairmont Copley Plaza Hotel, Boston, MA

Course Directors: Samuel Z. Goldhaber, MD,
Paul M. Ridker, MD

For further information: Tel: (617) 384-8600
Email: www.cme.hms.harvard.edu/courses/thrombosis

Brigham and Women's Hospital,
Cardiovascular Division website:
www.heartrdoc.org

This publication is made possible by an educational grant from
Novartis Pharmaceuticals Corporation

© 2006 Brigham and Women's Hospital, Boston, Massachusetts, which is solely responsible for the contents. The opinions expressed in this publication do not necessarily reflect those of the publisher or sponsor, but rather are those of the author based on the available scientific literature. Publisher: **SNELL Medical Communication Inc.** in cooperation with Brigham and Women's Hospital, Boston, Massachusetts. *Cardiology Rounds* is a registered trade mark of SNELL Medical Communication Inc. All rights reserved. The administration of any therapies discussed or referred to in *Cardiology Rounds* should always be consistent with the recognized prescribing information as required by the FDA. **Snell Medical Communication Inc.** is committed to the development of superior Continuing Medical Education.